ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53, and mismatch repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM)
Posted on: Jul 18, 2017 03:53PM
Triple-Negative Breast Cancer's Response to Carboplatin Before Surgery Seems Affected By BRCA1/2 Mutation Status
July 14, 2017
In the GeparSixto study, women with a BRCA1 or BRCA2 mutation responded better to chemotherapy before surgery without carboplatin, while women without a mutation had better outcomes when carboplatin was added to the chemotherapy regimen. Read more...